...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >TAMSULOSIN/SOLIFENACIN FIXED-DOSE COMBINATION TABLET FOR THE TREATMENT OF MALE LOWER URINARY TRACT SYMPTOMS
【24h】

TAMSULOSIN/SOLIFENACIN FIXED-DOSE COMBINATION TABLET FOR THE TREATMENT OF MALE LOWER URINARY TRACT SYMPTOMS

机译：Tamsulosin / solifenacin固定剂量组合片剂用于治疗男性低尿路症状

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Men reporting mixed storage and voiding lower urinary tract symptoms (LUTS) often experience persisting storage LUTS after initial treatment. Combination therapy of an alpha-adrenergic antagonist and an antimuscarinic is increasingly recognized as a therapy option. Clinical trials have combined tamsulosin (0.4 mg) with different doses of solifenacin. In the SATURN study, greater efficacy benefits were observed for moderate to severe storage symptoms. Single tablet administration may offer improved compliance. Accordingly, the NEPTUNE study researched fixed-dose combination (FDC) therapy for mixed LUTS, using tamsulosin (oral controlled administration system formulation), with solifenacin (6 or 9 mg). The FDC containing tamsulosin and solifenacin 6 mg improved storage and voiding LUTS, with no additional benefit from the higher solifenacin dose. During the open-label extension study, symptom improvement was maintained. Adverse events reflected the known effects of the component therapies. Acute urinary retention, an adverse event of special interest, was seen in only a small number of treated men.
机译：报告混合储存和空隙下尿路症状（LUTS）经常在初始治疗后经常经历持久的储存LUT。 α-肾上腺素能拮抗剂和抗血清胰岛素的组合治疗越来越被认为是治疗选择。临床试验用不同剂量的索氨仑组合蛋白酶（0.4mg）。在土星研究中，观察到中度至严重储存症状的更高疗效益处。单位平板电脑管理可以提供改善的合规性。因此，海王星研究采用甘草蛋白（口服对照给药系统制剂）的混合LUT的预防剂量组合（FDC）治疗，用Solifencin（6或9mg）。 FDC含有Tamsulosin和Solifenacin 6mg改进的储存和空隙LUT，没有额外的溶剂剂剂量。在开放标签扩展研究期间，维持症状改善。不良事件反映了组分疗法的已知效果。急性尿潴留，特别兴趣的不良事件，只在少数治疗的男性中看到。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号